UNSPSC 42296006: Vascular grafts

In this classification, this commodity indicates a product used as a graftable specimen of a vein in a medical setting. US FDA regulates Vascular grafts under 21 CFR 870.3450 and under FDA product code DSY. Most nations, for tariff and trade purposes, schedule these products under HS 902129.

UNSPSC 42296006 Vascular grafts is a Commodity code that shows limited recent state and local procurement activity aligned with its nominal scope. The code's abstract title does not reflect the work being solicited under it in the available recent opportunities. One identified opportunity—a Sourcewell cooperative purchasing RFP for law enforcement equipment issued on behalf of multiple Washington counties and thousands of participating public entities nationwide—bears no relationship to vascular grafts or any medical device category. Two other recent opportunities solicited cardiac rhythm management implantable devices and spinal implants respectively, which are surgical implants rather than vascular grafts as the code names them. The mismatch between the code designation and the actual scope of recent solicitations suggests either misclassification in the state and local procurement systems or minimal genuine activity under the vascular grafts commodity.

The recent opportunities that do appear come from public teaching hospitals in Texas: the University Medical Center of El Paso issued RFP #784-03-26-001 (due April 29, 2026) to establish a dual-vendor framework for pacemakers, implantable cardioverter-defibrillators, and cardiac resynchronization therapy devices, and the University of Texas Health Science Center at San Antonio issued RFP 745-26-P04 (due March 10, 2026) for spinal implants on a bill-only basis at its new 144-bed Multispecialty and Research Hospital. Both solicitations required comprehensive product portfolios, clinical evidence, and vendor support capabilities, with evaluations weighted toward product quality and cost. Neither opportunity discloses set-aside restrictions or award values. The code shows no identifiable geographic concentration or repeat buying patterns; pursuit depends on vendor alignment with the implantable device categories actually being solicited rather than vascular grafts per se.